G1 Therapeutics, an oncology therapy developer spun out of North Carolina University. has filed for a $115m initial public offering that will provide an exit for MedImmune, a subsidiary of pharmaceutical firm AstraZeneca.
{iframe}http://www.globaluniversityventuring.com/article.php/5772/g1-goes-for-115m-ipo{/iframe}